{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:59:50Z","timestamp":1790773190745,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T00:00:00Z","timestamp":1279411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:p>Gupta S, Fricker FJ, Gonz\u00e1lez\u2010Peralta RP, Slayton WB, Schuler PM, Dharnidharka VR. Post\u2010transplant lymphoproliferative disorder in children: Recent outcomes and response to dual rituximab\/low\u2010dose chemotherapy combination.\u2028Pediatr Transplantation 2010: 14:896\u2013902. \u00a9 2010 John Wiley &amp; Sons A\/S.<\/jats:p><jats:p><jats:bold>Abstract:\u2002<\/jats:bold> PTLD is a major complication after transplantation. Treatment options for PTLD are not standardized, usually sequential, starting with reduction in immunosuppression. Recently, we have used a dual combination of rituximab and reduced dose chemotherapy (R\/C) directly after failed RI. We retrospectively identified 30 pediatric PTLD cases across four organ systems at our center from 1995 to 2008. We assessed recent outcomes of PTLD in children, comparing the responses to different regimens. Two\u2010yr failure\u2010free survival was best in renal and heart recipients (80\u201388%), followed by liver (57%) and lung (0%). Of note, two patients were Epstein\u2013Barr peripheral blood viral load low positive but tumor EBER negative. Three patients had no detectable viral load but were EBER positive. The R\/C regimen (n\u2003=\u20038) had the highest CR rate (100%), low recurrence (12%) and lowest mortality (12%). Interferon (n\u2003=\u20034) had 75% CR, 33% recurrence and 25% mortality. Rituximab\/prednisone (n\u2003=\u20035) had 80% CR, 50% recurrence and 20% mortality. Other chemotherapy (n\u2003=\u20037, including all 4 T\u2010cell PTLDs) had 57% CR, 0% recurrence and 14% mortality. Direct dual R\/C combination therapy after failed RI is effective and offers another treatment option for B\u2010cell PTLD.<\/jats:p>","DOI":"10.1111\/j.1399-3046.2010.01370.x","type":"journal-article","created":{"date-parts":[[2010,7,19]],"date-time":"2010-07-19T01:22:22Z","timestamp":1279502542000},"page":"896-902","source":"Crossref","is-referenced-by-count":35,"title":["Post\u2010transplant lymphoproliferative disorder in children: Recent outcomes and response to dual rituximab\/low\u2010dose chemotherapy combination"],"prefix":"10.1111","volume":"14","author":[{"given":"Sushil","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Fricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regino P.","family":"Gonz\u00e1lez\u2010Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Slayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela M.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas R.","family":"Dharnidharka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,18]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-007-0582-3"},{"key":"e_1_2_7_3_2","first-page":"2","article-title":"Classification of the posttransplant lymphoproliferative disorders: From the past to the present","volume":"14","author":"Swerdlow SH","year":"1997","journal-title":"Semin Diagn Pathol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181761659"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02167.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0377"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01098.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805193182013"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2006.00284.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"crossref","first-page":"213a","DOI":"10.1182\/blood.V104.11.746.746","article-title":"Anti\u2010CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid organ transplantation: Multicenter experience from a registry and from a prospective clinical trial","volume":"104","author":"Webber SA","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199103000-00005"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90043-4"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.9.3333.bloodjournal8693333"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008263226895"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.074"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10595"},{"key":"e_1_2_7_17_2","first-page":"17","volume-title":"Post\u2010Transplant Lymphoproliferative Disorders","author":"Dharnidharka VR","year":"2009"},{"key":"e_1_2_7_18_2","first-page":"107","article-title":"Malignancy and post transplant lymphoproliferative disorder (PTLD) in pediatric renal transplant recipients: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)","volume":"1","author":"Hebert D","year":"1998","journal-title":"Pediatr Transplant"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00318.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70173-2"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.4.9901013"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199608150-00012"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2008.00914.x"},{"key":"e_1_2_7_24_2","first-page":"94","article-title":"The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients","volume":"70","author":"Younes BS","year":"2000","journal-title":"Transplantation"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)67933-6"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105233242102"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4961"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000144333.19106.58"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199812270-00035"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200101000-00005"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200104270-00012"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2009.01181.x"},{"issue":"10","key":"e_1_2_7_33_2","first-page":"3945S","article-title":"A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post\u2010transplant lymphoproliferative disorder following solid organ transplantation","volume":"9","author":"Orjuela M","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000258647.50947.78"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000295987.12996.19"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02772.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2009.01258.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2008.00328.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90513-8"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.30.11.2826-2829.1992"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.11.6546-6550.2003"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3046.2010.01370.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3046.2010.01370.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:40:07Z","timestamp":1697269207000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3046.2010.01370.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,18]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1399-3046.2010.01370.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3046.2010.01370.x","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,18]]}}}